Systemic anti-inflammatory treatment of atopic dermatitis during conception, pregnancy and breatsfeeding: Interdisciplinary expert consensus in Northern Europe
Deleuran, M.; Dezfoulian, Bita; J. Elberlinget al.
2024 • In Journal of the European Academy of Dermatology and Venereology, p. 1-11
Systemic anti-inflammatory treatment of atopic dermatitis during conception, pregnancy and breastfeeding Interdisciplinary expert consensus in Northern Europe.pdf
[en] Treating atopic dermatitis (AD) in pregnant or breastfeeding women, and in women and men with AD aspiring to be parents is difficult and characterized by uncertainty, as evidence to inform decision-making on systemic anti-inflammatory treatment is limited. This project mapped consensus across dermatologists, obstetricians and patients in Northwestern Europe to build practical advice for managing AD with systemic anti-inflammatory treatment in men and women of reproductive age. Twenty-one individuals (sixteen dermatologists, two obstetricians and three patients) participated in a two-round Delphi process. Full consensus was reached on 32 statements, partial consensus on four statements and no consensus on four statements. Cyclosporine A was the first-choice long-term systemic AD treatment for women preconception, during pregnancy and when breastfeeding, with short-course prednisolone for flare management. No consensus was reached on second-choice systemics preconception or during pregnancy, although during breastfeeding dupilumab and azathioprine were deemed suitable. It may be appropriate to discuss continuing an existing systemic AD medication with a woman if it provides good disease control and its benefits in pregnancy outweigh its risks. Janus kinase (JAK) inhibitors, methotrexate and mycophenolate mofetil should be avoided by women during preconception, pregnancy and breastfeeding, with medication-specific washout periods advised. For men preconception: cyclosporine A, azathioprine, dupilumab and corticosteroids are appropriate; a 3-month washout prior to conception is desirable for methotrexate and mycophenolate mofetil; there was no consensus on JAK inhibitors. Patient and clinician education on appropriate (and inappropriate) AD treatments for use in pregnancy is vital. A shared-care framework for interdisciplinary management of AD patients is advocated and outlined. This consensus provides interdisciplinary clinical guidance to clinicians who care for patients with AD before, during and after pregnancy. While systemic AD medications are used uncommonly in this patient group, considerations in this article may help patients with severe refractory AD.
Disciplines :
Dermatology
Author, co-author :
Deleuran, M.
Dezfoulian, Bita ; Centre Hospitalier Universitaire de Liège - CHU > > Service de dermatologie
Systemic anti-inflammatory treatment of atopic dermatitis during conception, pregnancy and breatsfeeding: Interdisciplinary expert consensus in Northern Europe
Publication date :
2024
Journal title :
Journal of the European Academy of Dermatology and Venereology
Vestergaard C, Wollenberg A, Barbarot S, Christen-Zaech S, Deleuran M, Spuls P, et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. J Eur Acad Dermatol Venereol. 2019;33:1644–1659.
Kemmett D, Tidman MJ. The influence of the menstrual cycle and pregnancy on atopic dermatitis. Br J Dermatol. 1991;125:59–61.
Cho S, Kim HJ, Oh SH, Park CO, Jung JY, Lee KH. The influence of pregnancy and menstruation on the deterioration of atopic dermatitis symptoms. Ann Dermatol. 2010;22:180–185.
Balakirski G, Novak N. Atopic dermatitis and pregnancy. J Allergy Clin Immunol. 2022;149:1185–1194.
Østensen M, Khamashta M, Lockshin M, Parke A, Brucato A, Carp H, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther. 2006;8:209.
Nelson-Piercy C, Vlaev I, Harris K, Fischer-Betz R. What factors could influence physicians' management of women of childbearing age with chronic inflammatory disease? A systematic review of behavioural determinants of clinical inertia. BMC Health Serv Res. 2019;19:863.
Pfaller B, Jose Yepes-Nunez J, Agache I, Akdis CA, Alsalamah M, Bavbek S, et al. Biologicals in atopic disease in pregnancy: an EAACI position paper. Allergy. 2021;76:71–89.
Vestergaard C, Wollenberg A, Thyssen JP. European task force on atopic dermatitis (ETFAD) position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. J Eur Acad Dermatol Venereol. 2020;34:426–427.
Wollenberg A, Kinberger M, Arents B, Aszodi N, Barbarot S, Bieber T, et al. European dermatology forum. Living EuroGuiDerm Guideline for the Systemic Treatment of Atopic Eczema 2022. Available at: https://www.edf.one/home/Guidelines/EuroGuiDerm-2022.html. (last accessed June 2022).
Heilskov S, Deleuran MS, Vestergaard C. Immunosuppressive and immunomodulating therapy for atopic dermatitis in pregnancy: an appraisal of the literature. Dermatol Ther (Heidelb). 2020;10:1215–1228.
Wollenberg A, Kinberger M, Arents B, Aszodi N, Barbarot S, Bieber T, et al. Living EuroGuiDerm guideline for the systemic treatment of atopic eczema. 2022 Available at: https://guidelines.edf.one//guidelines/atopic-ezcema. (last accessed September 2022).
Gerbens LA, Boyce AE, Wall D, Barbarot S, de Booji RJ, Deleuran M, et al. TREatment of ATopic eczema (TREAT) registry taskforce: protocol for an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema registries. Trials. 2017;18:87.
Simpson EL, Bruin-Weller M, Flohr C, Ardern-Jones MR, Barbarot S, Deleuran M, et al. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the international eczema council. J Am Acad Dermatol. 2017;77:623–633.
Sastre J, Baldrich ES, Armario Hita JC, Herráez L, Jáuregui I, Martín-Santiago A, et al. Consensus on the clinical approach to moderate-to-severe atopic dermatitis in Spain: a Delphi survey. Dermatol Res Pract. 2020;2020:1524293.
Remitz A, De Pità O, Mota A, Serra-Baldrich E, Vakirlis E, Kapp A. Position statement: topical calcineurin inhibitors in atopic dermatitis. J Eur Acad Dermatol Venereol. 2018;32:2074–2082.
Boguniewicz M, Alexis AF, Beck LA, Block J, Eichenfield LF, Fonacier L, et al. Expert perspectives on management of moderate-to-severe atopic dermatitis: a multidisciplinary consensus addressing current and emerging therapies. J Allergy Clin Immunol Pract. 2017;5:1519–1531.
Thyssen JP, Berents T, Bradley M, Deleuran M, Grimstad Ø, Korhonen L, et al. Clinical management of atopic dermatitis in adults: mapping of expert opinion in 4 Nordic countries using a modified Delphi process. Acta Derm Venereol. 2020;100:adv00015.
Thyssen JP, Heegaard S, Ivert L, Remitz A, Agner T, Bruin-Weller M, et al. Management of ocular manifestations of atopic dermatitis: a consensus meeting using a modified Delphi process. Acta Derm Venereol. 2020;100:adv00264.
Schaller M, Almeida LMC, Bewley A, Cribier B, del Rosso J, Dlova NC, et al. Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea COnsensus 2019 panel. Br J Dermatol. 2020;182:1269–1276.
De Bruin-Weller M, Biedermann T, Bissonnette R, Deleuran M, Foley P, Girolomoni G, et al. Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies. Acta Derm Venereol. 2021;101:adv00402.
Chan TC, Wu N-L, Wong L-S, Cho YT, Yang CY, Yu Y, et al. Taiwanese dermatological association consensus for the management of atopic dermatitis: a 2020 update. J Formos Med Assoc. 2021;120:429–442.
Lebwohl M, Siegel M, Shankle L, Pisenti L, Yassine M, Van Vorhees S. A comprehensive survey assessing the family planning needs of women with psoriasis. Skin. 2018;2:S89.
De Simone C, Calabrese L, Balato A, Cannavò SP, Dattola A, Esposito M, et al. Psoriasis and its management in women of childbearing age: tools to increase awareness in dermatologists and patients. G Ital Dermatol Venereol. 2020;155:434–440.
Bermas BL. Paternal safety of anti-rheumatic medications. Best Pract Res Clin Obstet Gynaecol. 2020;64:77–84.
Götestam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75:795–810.
Semet M, Paci M, Saïas-Magnan J, Metzler-Guillemain C, Boissier R, Lejeune H, et al. The impact of drugs on male fertility: a review. Andrology. 2017;5:640–663.
Grosen A, Nersting J, Bungum M, Christensen LA, Schmiegelow K, Spanò M, et al. Sperm DNA integrity is unaffected by thiopurine treatment in men with inflammatory bowel disease. J Crohns Colitis. 2019;13:3–11.
Banerjee A, Scarpa M, Pathak S, Burra P, Sturniolo GC, Russo FP, et al. Inflammatory bowel disease therapies adversely affect fertility in men- a systematic review and meta-analysis. Endocr Metab Immune Disord Drug Targets. 2019;19:959–974.
Perez-Garcia LF, Dolhain R, Vorstenbosch S, Bramer W, van Puijenbroek E, Hazes JMW, et al. The effect of paternal exposure to immunosuppressive drugs on sexual function, reproductive hormones, fertility, pregnancy and offspring outcomes: a systematic review. Hum Reprod Update. 2020;26:961–1001.
Grosen A, Bellaguarda E, Nersting J, Hvas CL, Liljeqvist-Soltic I, Stein A, et al. Low-dose methotrexate therapy does not affect semen parameters and sperm DNA. Inflamm Bowel Dis. 2022;28:1012–1018.
Perez-Garcia LF, Röder E, Van Adrichem R, van Koppen LJK, Zirkzee E, Van Doorn M, et al. What is the effect of methotrexate on semen parameters of men diagnosed with immune-mediated diseases? Results of a prospective cohort study (iFAME-MTX). Ann Rheum Dis. 2022;81:84.
Sammaritano LR, Bermas BL, Chakravarty EE, Chambers C, Clowse MEB, Lockshin MD, et al. 2020 American College of Rheumatology Guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2020;72:529–556.
The Lancet Rheumatology. JAK inhibitors: fate in doubt for rheumatoid arthritis? Lancet Rheumatol. 2021;3:e161.
Chapin RE, Ball DJ, Radi ZA, Kumpf SW, Koza-Taylor PH, Potter DM, et al. Effects of the Janus kinase inhibitor, tofacitinib, on testicular Leydig cell hyperplasia and adenoma in rats, and on prolactin signaling in cultured primary rat Leydig cells. Toxicol Sci. 2017;155:148–156.
Bosma A, Gerbens L, Middelkamp-Hup M, Spuls P. Paternal and maternal use of dupilumab in patients with atopic dermatitis: a case series. Clin Exp Dermatol. 2021;46:1089–1092.
Hamann CR, Egeberg A, Wollenberg A, Gislason G, Skov L, Thyssen JP. Pregnancy complications, treatment characteristics and birth outcomes in women with atopic dermatitis in Denmark. J Eur Acad Dermatol Venereol. 2019;33:577–587.
Saito-Abe M, Yamamoto-Hanada K, Pak K, Sato M, Irahara M, Mezawa H, et al. Association of maternal history of allergic features with preterm pregnancy outcomes in the Japan environment and children's study. Int Arch Allergy Immunol. 2021;182:650–662.
Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1–s106.
Akhtar NH, Khosravi-Hafshejani T, Akhtar D, Dhadwal G, Kanani A. The use of dupilumab in severe atopic dermatitis during pregnancy: a case report. Allergy Asthma Clin Immunol. 2022;18:9.
Lobo Y, Lee RC, Spelman L. Atopic dermatitis treated safely with dupilumab during pregnancy: a case report and review of the literature. Case Rep Dermatol. 2021;13:248–256.
Khamisy-Farah R, Damiani G, Kong JD, Wu JH, Bragazzi NL. Safety profile of Dupilumab during pregnancy: a data mining and disproportionality analysis of over 37,000 reports from the WHO individual case safety reporting database (VigiBase). Eur Rev Med Pharmacol Sci. 2021;25:5448–5451.
WHO. Breastfeeding. 2021. Available at: https://www.who.int/health-topics/breastfeeding#tab=tab_1. (last accessed June 2022).
US National Library of Medicine. Drugs and Lactation Database (LactMed). 2022. Available at: https://www.ncbi.nlm.nih.gov/books/NBK576870/. (last accessed September 2022).
Singh M, Qualie J, Currie A, Howarth ES, Khare MM. Is breastfeeding safe with azathioprine? Obstet Med. 2011;4:104–107.
Angelberger S, Reinisch W, Messerschmidt A, Miehsler W, Novacek G, Vogelsang H, et al. Long-term follow-up of babies exposed to azathioprine in utero and via breastfeeding. J Crohns Colitis. 2011;5:95–100.
Bernard N, Gouraud A, Paret N, Cottin J, Descotes J, Vial T. Azathioprine and breastfeeding: long-term follow-up. Fundam Clin Pharmacol. 2013;27(Suppl. 1):12.
